Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001776-13-DE

Enrollment

Registered

2006-09-26

Start date

2005-08-05

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Interventions

Product Name: Levetiracetam Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: clinical definite MS mild to medium spasticity Penn score at least 1 minimum age 18 informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: known intolerance towards Levetiracetam EDSS score > 6.5 pregnant or breast feading women severe renal and liver impairment other severe conditions

Design outcomes

Primary

Measure	Time frame
Main Objective: Reduction of spasticity measrued in clinical scores (Ashworth an Penn scale);Secondary Objective: qualitiy of life safety side effects;Primary end point(s): improvement of spasticity scores	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026